Dermatologic Adverse Events Related to the PI3Kα Inhibitor Alpelisib (BYL719) in Patients with Breast Cancer

PURPOSE: Rash develops in approximately 50% of patients receiving alpelisib for breast cancer, often requiring dose modifications. Here, we describe the clinicopathologic, laboratory, and management characteristics of alpelisib-related dermatologic adverse events (dAEs). METHODS: A single center ret...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res Treat
Hlavní autoři: Wang, Diana G., Barrios, Dulce M., Blinder, Victoria S., Bromberg, Jacqueline F., Drullinsky, Pamela R., Funt, Samuel A., Jhaveri, Komal L., Lake, Diana E., Lyons, Tomas, Modi, Shanu, Razavi, Pedram, Sidel, Michelle, Traina, Tiffany A., Vahdat, Linda T., Lacouture, Mario E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7398571/
https://ncbi.nlm.nih.gov/pubmed/32613539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05726-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky